Module

mTOR Inhibition in Solid Tumors: Emerging Data and Ongoing Trials

Source: Attacking the Signal at the Switch: Unraveling the Mysteries of mTOR Inhibition in Multiple Tumor Types

mTOR Inhibition in Solid Tumors: Emerging Data and Ongoing Trials

CME Program Director: Jose Baselga, MD

Faculty:
Matthew Kulke, MD

CME CREDIT INFORMATION

Release Date: 05/30/08

Expiration Date: 05/29/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 0.8 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Distinguish the rationale for the use of mTOR inhibition in the treatment of solid tumors
Discuss recent clinical trial results regarding the activity of mTOR inhibitors in solid tumors, including breast, colorectal, endometrial, neuroendocrine, and sarcoma
Describe the toxicity profiles of mTOR inhibitors, as observed in recent trials
Cite ongoing clinical trials of mTOR inhibitors in the treatment of solid tumors

Topics covered include:

Introduction
Rationale for mTOR Inhibition in Solid Tumors
Clinical Development of mTOR Inhibitors: Phase I Studies
Activity of mTOR Inhibitors in Solid Tumors
Conclusion

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.